基于CT的Delta影像组学预测多发性骨髓瘤诱导治疗反应:利用CT特征变化
该研究回顾性纳入131例新诊断多发性骨髓瘤患者,基于基线及诱导后CT提取肋骨、胸骨柄和胸椎的Delta影像组学特征,构建多区域模型预测治疗反应。训练集AUC为0.855,独立验证集AUC为0.842;24小时尿蛋白作为生物学锚点未统计学提升预测精度,但提供系统性肾脏负荷背景。
要点
- 多区域Delta影像组学特征(RadDeltaAll)在训练集AUC 0.855、验证集AUC 0.842,稳定性优于单部位模型。
- 24hU-Pro作为生物学锚点未统计学提升预测精度,但提供系统性肾脏负荷背景。
- 研究强调定量、骨骼感知分析对个体化诱导治疗决策的临床必要性。
核心结论
- 基于CT的Delta影像组学是评估多发性骨髓瘤治疗反应的稳健无创生物标志物,多区域影像组学特征为预测效力的主要引擎,24hU-Pro为不可或缺的生物学参考。
研究设计与样本
- 回顾性研究,纳入131例新诊断多发性骨髓瘤患者(2019年4月至2024年11月),按7:3比例分为训练集和验证集;基线与诱导后CT图像(平均间隔132天)采用高分辨率锐利核重建;经观察者间稳定性筛选(ICC>0.90)后从肋骨、胸骨柄和胸椎提取Delta影像组学特征;采用mRMR和LASSO回归进行稳定性优先的特征选择。
诊断标准与关键数值
- 训练集整合框架AUC为0.855。
- 独立验证集中综合RadDeltaAll模型AUC为0.842。
- ISS分期I/II/III分别占19.9%/29.0%/51.1%,在各队列间平衡。
临床应用与阅片要点
- 作者认为定量、骨骼感知分析在指导个体化诱导治疗方面具有临床必要性。
- 24hU-Pro可作为生物学锚点提供系统性肾脏负荷背景,但未统计学提升预测精度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This work established and validated a radiomics-driven framework to quantify therapeutic response in multiple myeloma (MM). By leveraging CT-based Delta features, we aimed to delineate sub-visual temporal changes and assess their incremental predictive value beyond conventional clinical biomarkers.
METHODS: We retrospectively evaluated 131 newly diagnosed MM patients (April 2019-November 2024), partitioned into training and validation cohorts (7:3 ratio). Baseline and post-induction CT images (mean interval: 132 days), reconstructed via high-resolution sharp kernels, served as the basis for analysis. Following a rigorous inter-observer stability filter (ICC > 0.90), Delta-radiomic features were extracted from the ribs, manubrium, and thoracic spine. A stability-first selection pipeline, utilizing mRMR and LASSO regression, identified the most robust signatures for model construction.
RESULTS: ISS staging (I/II/III: 19.9%/29.0%/51.1%) was balanced across cohorts. The multi-regional radiomics signature (RadDeltaAll) demonstrated superior stability compared to single-site models. In the training set, the integrated framework yielded an AUC of 0.855. In the independent validation cohort, while single-site performance varied, the comprehensive RadDeltaAll model maintained high diagnostic stability . AUC = 0.842. Notably, the clinical biomarker 24hU-Pro was retained as a "biological anchor"; although it did not statistically enhance predictive accuracy, it provided essential context for systemic renal burden without compromising model integrity.
CONCLUSION: CT-based Delta radiomics constitutes a robust, non-invasive biomarker for MM response assessment. While 24hU-Pro serves as an indispensable biological reference, the multi-regional radiomic signature remains the primary engine of predictive power. This underscores the clinical necessity of quantitative, skeleton-aware analysis in steering individualized induction therapy. MM: Multiple myeloma; CT: Computed tomography; ROI: Region of interest; AUC: Area under the curve; ESM: Electronic supplementary material; WBLDCT: Whole-body low-dose computed tomography; IMWG: International Myeloma Working Group; LASSO: Least Absolute Shrinkage and Selection Operator; mRMR: minimum Redundancy Maximum Relevance; SVM: Support Vector Machine; RF: Random Forest; XGBoost: Extreme Gradient Boosting; GLCM: Gray-Level Co-occurrence Matrix; GLRLM: Gray-Level Run-Length Matrix; GLSZM: Gray-Level Size Zone Matrix; NGTDM: Neighboring Gray-Tone Difference Matrix; DSC: Dice Similarity Coefficient; DCA: Decision Curve Analysis.
引用
- Qu Z, Zhao X, He M, et al. A radiomics-driven approach for predicting response to induction therapy in multiple myeloma: Leveraging CT-based delta features. Eur J Radiol. 2026. PMID: 41818906. doi:10.1016/j.ejrad.2026.112779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。